Cannulated intravaginal injection technique (CIVIT) A Novel Vaginal Injection Technique.
Leylek O., Peker BH., Demircivi E., Peker H.
Retrospective Study with a reported sample of 44, published in Sci Rep (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Sci Rep (2025)
- Country
- England
- Reported sample size
- 44
- Source database
- PubMed
- PMID
- 40038371
- DOI
- 10.1038/s41598-025-91069-x
Abstract (original English)
Non-surgical procedures such as fillers, PRP and derivatives, energy-based devices and adipose derivate mesenchymal stem cell treatments are begun to be used in women genital area for both functional and aesthetic purposes. After theproduction of injectable HA for genital use, patients were able to benefit more effectively from these applications and its use in the vagina became more common. In our study, we aimed to demonstrate a new intravaginal injection technique, Cannulated Intravaginal Injection Technique (CIVIT) that we can perform vaginal injection more homogenously and less traumatic and more effectively to the entire vaginal mucosa. Retrospectively, the data of 44 patients who underwent intravaginal injection of HA manufactured for genital use at a private Female Health Clinic were analyzed. Of the 44 patients, 21 were injected using the random needling technique, and 22 were injected using CIVIT. All patients had symptoms of genitourinary syndrome (GUS), a vaginal health index below 15, and were compared based on the Female Sexual Function Index (FSFI) and visual analogue scale (VAS) for GUS before and after the procedures. It was observed that all post-injection values, except for FSFI arousal (p = 0.539), were statistically significantly higher in the CIVIT group (P = 0.001). Post injection dryness, dyspareunia and discomfort values decreased significantly in the C
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.